Compare ADMA Biologics Inc (ADMA) vs Allegion PLC (ALLE) Price & Performance
Price performance
Price movement over the last 24 hours
Key statistics
Key statistics
ADMA Biologics Inc vs Allegion PLC — how do they compare? ADMA Biologics Inc trades at $9.18 (market cap $2.13B), while Allegion PLC trades at $135.08 (market cap $11.97B). The key difference: Allegion PLC is far larger — about 5.6× ADMA Biologics Inc's market cap, and Allegion PLC pays a 1.52% dividend while ADMA Biologics Inc pays none. Which is the better fit depends on your goals.
| ADMA | ALLE | |
|---|---|---|
Market Cap | $2.13B | $11.97B |
Sector | Health | Industrials |
52-Week High | $20.38 | $179.77 |
52-Week Low | $7.60 | $125.65 |
Enterprise Value | $2.20B | $13.69B |
Dividend Yield | — | 1.52% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
ADMA trades at $9.16, up 2.35% today, with a bullish technical signal from moving averages and oscillators. The company reported strong profitability with a 32.43% net income margin and 43.3% ROE for 2025, though recent EPS results were mixed. Analyst consensus is strongly bullish with an $19.00 price target, but multiple class action lawsuits filed in July 2026 alleging securities fraud create significant near-term uncertainty.
The stock offers substantial upside to analyst targets if legal challenges are resolved favorably, supported by robust fundamentals and projected cash flow growth. Primary risks include the outcome of ongoing litigation and potential reputational damage. Investors should weigh strong financial performance against elevated legal and sentiment risks before establishing a position.
ALLE trades at $139.32, down 0.9% on the day, with a bullish technical signal and strong fundamentals including a 15.24% net margin and 34.18% ROE. Recent earnings show mixed results with a Q3 2025 beat but Q4 2025 and Q1 2026 misses. The company maintains robust cash flow from operations and has announced a $0.55 dividend for June 2026. News highlights product innovations like the Schlage Sense Pro smart deadbolt and participation in industry conferences.
Outlook is supported by analyst consensus with a $152.50 price target and no sell ratings, though risks include rising costs and international market weakness. The stock offers growth potential from Americas strength and acquisitions, but investors should monitor margin pressures and debt levels.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About ADMA Biologics Inc
ADMA Biologics is a biopharmaceutical company specializing in plasma-derived therapies for immunodeficient patients. Key products like ASCENIV and BIVIGAM treat primary humoral immunodeficiency and help prevent infectious diseases.
Read more on ADMA →About Allegion PLC
Allegion is a global security products company with a portfolio of leading brands, such as Schlage, von Duprin, and LCN. The Ireland-domiciled company was created via a spinoff transaction from Ingersoll-Rand in December 2013. In fiscal 2021, Allegion generated 68% of sales in the United States. The company mainly competes with Swedish-based Assa Abloy AB and Switzerland-based Dormakaba.
Read more on ALLE →
